Idexx Laboratories Inc (IDXX) Gross Profit Margin starting from the third quarter 2026 to third quarter 2025, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Idexx Laboratories Inc  (NASDAQ: IDXX)


Idexx Laboratories Inc's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IDXX Gross Profit Margin (Sep 30 2026)
Q3 		(Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Revenue Change 9.95 %
Seq. Revenue Change -0.19 %
Revenue In Millions $1,214.24
Gross Profit Margin 62.94 %
Gross Profit Margin Total Ranking # 1255
Gross Profit In Millions $764.30
Y / Y Gross Profit Change 11.85 %
Seq. Gross Profit Change -1.9 %


Commenting Third Quarter 2026 Gross Profit Margin
Idexx Laboratories Inc experienced contraction in Gross Profit by -1.9 % to $1,214 millions and Revenue by -0.19 %, while Gross Profit Margin fell to 62.94 %, above company*s average Gross Profit Margin.


Observing third quarter 2026 results within In Vitro & In Vivo Diagnostic Substances industry only one other company has achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 1255, from total ranking in the previous quarter at 1473.
Learn about Gross Margin
IDXX's Gross Profit Margin third quarter 2026 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 2
Healthcare Sector # 231
Overall # 1243

Gross Profit Margin Statistics
High Average Low
64.04 % 57.5 % 51.72 %
(Jun 30 2026)   (Dec 31 2011)


IDXX Gross Income Trends • More of IDXX's Profitabilty Ratios • IDXX Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
IDXX's Cumulative Gross Profit Margin
In Vitro & In Vivo Diagnostic Substances Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
IDXX's Gross Profit Margin Profitability versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for IDXX's Competitors
Gross Profit Margin Profit Margin for Idexx Laboratories Inc's Suppliers
Gross Profit Margin Profit Margin for IDXX's Customers

You may also want to know
IDXX's Annual Growth Rates IDXX's Profitability Ratios IDXX's Asset Turnover Ratio IDXX's Dividend Growth
IDXX's Roe IDXX's Valuation Ratios IDXX's Financial Strength Ratios IDXX's Gross Profit Growth
IDXX's Roa IDXX's Inventory Turnover Ratio IDXX's Growth Rates IDXX's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2026, within In Vitro & In Vivo Diagnostic Substances Industry Gross Profit MarginSep 30 2026 MRQ Gross ProfitSep 30 2026 MRQ Revenue
Myriad Genetics Inc   67.93 %$ 137.700  Millions$ 202.700  Millions
Idexx Laboratories Inc  62.94 %$ 764.298  Millions$ 1,214.237  Millions
Lantheus Holdings Inc   62.43 %$ 243.412  Millions$ 389.913  Millions
Neogen Corporation  47.38 %$ 105.600  Millions$ 222.900  Millions
Quidelortho Corp  46.79 %$ 289.600  Millions$ 618.900  Millions
Alpha Teknova Inc   37.99 %$ 4.826  Millions$ 12.704  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.